AstraZeneca Drug Could Help Keep A Common Breast Cancer At Bay - Data Intelligence

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 1, 2025-

AstraZeneca Drug Could Help Keep A Common Breast Cancer At Bay - Data Intelligence

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. CHICAGO — Too often, cancer has a way of evading treatment. Tumors that were held in check begin to spread anew, forcing doctors to try different drugs in a desperate race to keep malignant cells from multiplying. For a common type of breast cancer, this usually happens because of changes in a gene called ESR1. Mutations there can drive cancer gro…

AstraZeneca's Camizestrant Shows Promise in Prolonging Treatment Benefits for Common Breast Cancer

AstraZeneca’s experimental drug camizestrant has demonstrated promising results in extending the benefits of initial breast cancer treatment, according to new data presented at the American Society of Clinical Oncology’s annual meeting. The study focused on patients with hormone receptor-positive, HER2-negative advanced breast cancer, which accounts for approximately 70% of breast cancer cases. These patients are typically treated with hormone t…

Camizestrant/CDK4/6 Inhibition Boosts PFS in ESR1+ Advanced Breast Cancer

Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.

Camizestrant Betters PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– breast cancer in the SERENA-6 trial.